Deep vein thrombosis misdiagnosis settlements range widely, with recorded verdicts exceeding $20 million in severe amputation cases and mean settlements averaging $662,000 across all cases studied. A 2025 Maryland case resulted in a $7.25 million verdict when a patient died from pulmonary embolism after anticoagulation treatment was stopped without proper follow-up screening. The highest-profile case involved a Massachusetts verdict of $20 million in March 2023, awarded to a patient who required above-the-knee amputation due to a missed DVT diagnosis.
The variation in these figures reflects the severity of injuries and the specific circumstances of care failure. Settlement amounts depend heavily on injury outcomes. Cases involving amputation, permanent disability, or death consistently result in multimillion-dollar awards, while cases with treatable complications or early intervention may settle for substantially less. A peer-reviewed analysis of 122 orthopedic-related medical malpractice cases from 1980 to 2023 found that when juries ruled in the plaintiff’s favor, the mean verdict reached $2.39 million—significantly higher than negotiated settlements, which averaged $662,000.
Table of Contents
- How Much Do DVT Misdiagnosis Cases Actually Settle For?
- Factors That Determine Settlement Value in DVT Misdiagnosis Claims
- Published High-Value Verdicts and What Drove Them
- Proving Medical Negligence in DVT Misdiagnosis Claims
- Why Settlement Values Vary So Dramatically Between Cases
- Statute of Limitations and Strategic Timing of Settlement Negotiations
- Common Clinical Scenarios Resulting in High-Value Settlements
How Much Do DVT Misdiagnosis Cases Actually Settle For?
Settlement figures in DVT misdiagnosis cases typically fall into three distinct ranges. Severe cases involving amputation, death, or permanent disability regularly exceed $5 million, with documented verdicts of $13.5 million, $15 million, and $20 million. Mid-range cases with significant complications but no amputation average between $1 million and $3 million. Less severe cases may settle for $500,000 or less, though precise figures for these cases are less frequently published because settlements are often confidential. The $7.25 million Maryland verdict from January 2025 illustrates how settlement amounts correlate directly with causation and injury severity. That case involved a physician who discontinued anticoagulation therapy without documenting clinical justification or arranging imaging follow-up—the patient subsequently died from pulmonary embolism.
The jury awarded damages that reflected both economic losses (medical expenses, lost wages) and non-economic damages (pain and suffering, loss of life). A 2012 Virginia case demonstrates the mid-range settlement: a $1.7 million award for a patient who died from post-surgical pulmonary embolism after DVT went undiagnosed during hospitalization. Geographic location and state damage caps significantly affect settlement values. Some states impose caps on non-economic damages that reduce overall awards, while others allow full recovery. This explains why similar cases in different jurisdictions may result in vastly different payments to plaintiffs. Additionally, cases that go to trial and result in jury verdicts consistently exceed negotiated settlements, sometimes by a factor of three or more.
Factors That Determine Settlement Value in DVT Misdiagnosis Claims
Injury severity is the primary driver of settlement value. Cases resulting in amputation typically settle or verdict for significantly more than cases where anticoagulation therapy prevented clot progression. An Illinois verdict of $15 million involved bilateral leg amputation—the loss of both limbs dramatically increased lifetime economic damages compared to unilateral amputation cases. A Michigan case that resulted in $1.1 million involved delayed arterial occlusion diagnosis following DVT, ultimately requiring amputation; without the amputation component, the same delayed diagnosis might have settled for $300,000 to $500,000. The patient’s age and earning capacity substantially affect damage calculations.
A 35-year-old engineer with 30 years of potential earning capacity will generate higher economic damage awards than a 72-year-old retiree with the same DVT misdiagnosis. Courts calculate future lost wages, lost benefits, and lifetime medical expenses based on actuarial tables and expert testimony. Death cases introduce special considerations: wrongful death statutes vary by state regarding which family members can recover and for what damages. Non-economic damages—pain and suffering, loss of enjoyment of life, emotional distress—represent a substantial portion of settlements but are more subjective and harder to quantify. Juries tend to award higher non-economic damages in cases where the patient endures permanent disability, extensive hospitalizations, or multiple surgeries. A cautionary limitation: many states have enacted damage caps specifically to reduce non-economic awards, meaning a $20 million verdict in Massachusetts might translate to only $8 million in a capped jurisdiction even with identical injuries.
Published High-Value Verdicts and What Drove Them
The $20 million Massachusetts verdict from March 2023 remains the highest recorded award for DVT-related amputation. The case involved a patient who presented with symptoms consistent with DVT—swelling, pain, warmth in the leg—but the condition was missed on initial evaluation. By the time DVT was correctly diagnosed, the clot had caused arterial compromise requiring above-the-knee amputation. The verdict reflected not only the permanent loss of limb function but also the patient’s documented age and career potential. An undisclosed jurisdictional case documented at $13.5 million involved similar facts: undiagnosed blood clot progressing to amputation-level arterial compromise.
These cases typically include testimony from vascular surgeons explaining that prompt diagnosis and anticoagulation would have preserved limb viability. medical expert testimony quantifying the difference between a patient with two functional legs and a patient who is now a bilateral amputee carries substantial weight with juries. The $1.7 million Virginia verdict from June 2012 demonstrates how post-surgical DVT cases settle even without amputation. The patient underwent surgery, developed DVT postoperatively, and the condition was not identified despite clinical presentation. The resulting pulmonary embolism proved fatal. The lower verdict amount compared to amputation cases reflects Virginia’s damage caps and the complexity of attributing death solely to DVT versus other surgical complications—though causation was ultimately established.
Proving Medical Negligence in DVT Misdiagnosis Claims
Negligence in DVT misdiagnosis requires demonstrating that a reasonably competent physician would have diagnosed the condition. Standard of care requires evaluation of clinical symptoms (unilateral leg swelling, calf pain, warmth), patient risk factors (immobility, recent surgery, cancer), and appropriate diagnostic imaging. Cases are strengthened when the physician documented clinical findings consistent with DVT but failed to order ultrasonography—the gold standard diagnostic test. Medical expert testimony is essential because jurors cannot independently evaluate whether a diagnosis was missed negligently or represents an unfortunate but non-negligent diagnostic error.
A Michigan case that settled for $1 million involved a patient with classic DVT symptoms who was discharged without imaging; the patient subsequently developed complications requiring treatment. The settlement was strong because the defendant’s own medical records documented symptoms that should have triggered diagnostic workup. A limitation in proving misdiagnosis: if the patient presented with atypical symptoms or the physician documented reasoning for not pursuing imaging (such as very low clinical suspicion based on specific exam findings), the negligence claim weakens. Additionally, if the patient received anticoagulation therapy shortly after diagnosis—even with a delay—some damage awards are reduced because the delay did not ultimately change outcomes. The timing of diagnosis relative to symptom onset therefore becomes critical: a 24-hour delay in an ambulatory patient may be more defensible than a 7-day delay in a hospitalized patient with documented risk factors.
Why Settlement Values Vary So Dramatically Between Cases
State law differences create enormous variability. Some jurisdictions cap non-economic damages at $250,000 or $500,000, while others permit unlimited non-economic awards. A case identical in facts might yield $8 million in an unrestricted state and $3 million in a capped state. Additionally, some states follow comparative negligence rules, reducing awards if the patient bears partial fault—for example, if a patient ignored discharge instructions or failed to follow up after hospitalization. Jury composition and venue also influence outcomes substantially. Urban juries tend to award higher amounts than rural juries in the same state, and juries in some regions are historically more sympathetic to medical malpractice plaintiffs.
This geographic variation explains why an Illinois verdict of $15 million and a Maryland verdict of $7.25 million—both involving serious outcomes—differ so significantly. The plaintiff’s attorney and defendant’s defense team also affect outcomes; experienced trial attorneys who effectively present expert testimony consistently achieve better settlements. A significant caveat: most cases never reach verdict. The mean settlement of $662,000 across 122 cases represents negotiated resolutions where both sides accept risk and uncertainty rather than proceeding to trial. When cases do reach jury verdict with plaintiff wins, the mean increases to $2.39 million—nearly 3.6 times higher. This gap suggests that cases proceeding to trial are either unusually strong (for plaintiffs) or defendants are making strategic errors in settlement negotiations. Understanding this dynamic is critical: a $662,000 settlement offer may undervalue a case with trial potential significantly exceeding $2 million.
Statute of Limitations and Strategic Timing of Settlement Negotiations
Most states impose a statute of limitations of 2 to 3 years from the date of misdiagnosis for medical malpractice claims, though some jurisdictions extend this period if the injury was not immediately apparent. This time constraint creates pressure on both sides: defendants want to close liability before trial dates approach, while plaintiffs’ attorneys must assess trial readiness and expert witness availability.
Settlement negotiations frequently intensify as trial approaches because trial costs are substantial—expert testimony, depositions, and attorney fees can exceed $150,000 for either side. The closer a case moves to trial, the more concrete the settlement value becomes; attorneys have clearer jury pool data, completed expert reports, and established legal precedents. A case that seemed worth $500,000 at year one may have clearer value of $1.2 million at year three when settlement discussions resume in proximity to trial.
Common Clinical Scenarios Resulting in High-Value Settlements
Post-surgical DVT represents a significant category of misdiagnosis claims. Patients undergoing orthopedic surgery, general surgery, or gynecologic procedures face elevated DVT risk for 10-14 days postoperatively. When hospitalized patients develop signs of DVT—swelling, pain, warmth—and these signs are attributed to normal post-surgical inflammation rather than investigated with ultrasonography, the resulting misdiagnosis can be catastrophic. The Michigan $1 million settlement involved exactly this scenario: a patient discharged with undiscovered postoperative DVT who subsequently developed complications requiring intervention. Missed DVT in the outpatient setting, where patients present to emergency departments or primary care offices with leg swelling, presents a different challenge. These cases hinge on whether clinical examination and patient history were documented thoroughly enough to trigger imaging.
The Massachusetts $20 million verdict involved a patient who presented with symptoms classic for DVT but the condition was initially missed—the subsequent amputation, combined with the straightforward nature of the misdiagnosis, drove the exceptionally high award. Outpatient misdiagnosis cases are often more defensible for plaintiffs because the diagnostic failure occurs in an environment with fewer competing demands and clearer decision-making time than a busy inpatient hospital ward. Cancer patients with DVT present a particularly challenging diagnostic scenario because these patients may have swelling from other causes (lymphedema, tumor mass effect, infection). However, cancer patients are also at substantially elevated thrombotic risk, making DVT more likely despite other potential explanations. A delayed diagnosis in this population can progress rapidly. While specific documented settlements for cancer-associated DVT misdiagnosis were not located in the research, the intersection of malignancy and thromboembolism is recognized as high-risk, and such cases typically settle within the $1-3 million range when misdiagnosis occurs despite documented risk factors.
- —